Relmada Therapeutics is dedicated to reshaping the standard of care for central nervous system disorders.
Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in advanced clinical development for the treatment of major depressive disorder (MDD).
Data from the Phase 2 trial with REL-1017 suggest rapid, robust, and sustained antidepressant effects with statistically significant improvements as compared to placebo on all tested efficacy measures (Fava 2022). The Phase 2 study data also confirm the very favorable safety and tolerability profile of REL-1017 seen in Phase 1 studies (Bernstein 2019). The U.S. Food and Drug Administration has granted Fast Track designations to REL-1017 for the treatment of MDD. The Phase 3 Reliance clinical trial program is underway with Reliance II and Reliance OLS ongoing and an expected initiation of additional clinical evaluations.